Pieter P Lestrade1,2, Robbert G Bentvelsen3, Alexander F A D Schauwvlieghe4, Steven Schalekamp5, Walter J F M van der Velden2,6, Ed J Kuiper3, Judith van Paassen7, Ben van der Hoven8, Henrich A van der Lee1,2, Willem J G Melchers1,2, Anton F de Haan9, Hans L van der Hoeven2,10, Bart J A Rijnders4, Martha T van der Beek3, Paul E Verweij1,2. 1. Department of Medical Microbiology, Radboud University Medical Center. 2. Center of Expertise in Mycology Radboud University Medical Center/CWZ, Nijmegen. 3. Department of Medical Microbiology, Leiden University Medical Center. 4. Department of Medical Microbiology and Infectious Disease, Erasmus Medical Center, Rotterdam. 5. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen. 6. Department of Hematology, Radboud University Medical Center, Nijmegen. 7. Department of Intensive Care, Leiden University Medical Center. 8. Department of Intensive Care, Erasmus Medical Center, Rotterdam. 9. Department of Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands. 10. Department of Intensive Care, Radboud University Medical Center, Nijmegen, the Netherlands.
Abstract
BACKGROUND: Triazole resistance is an increasing problem in invasive aspergillosis (IA). Small case series show mortality rates of 50%-100% in patients infected with a triazole-resistant Aspergillus fumigatus, but a direct comparison with triazole-susceptible IA is lacking. METHODS: A 5-year retrospective cohort study (2011-2015) was conducted to compare mortality in patients with voriconazole-susceptible and voriconazole-resistant IA. Aspergillus fumigatus culture-positive patients were investigated to identify patients with proven, probable, and putative IA. Clinical characteristics, day 42 and day 90 mortality, triazole-resistance profiles, and antifungal treatments were investigated. RESULTS: Of 196 patients with IA, 37 (19%) harbored a voriconazole-resistant infection. Hematological malignancy was the underlying disease in 103 (53%) patients, and 154 (79%) patients were started on voriconazole. Compared with voriconazole-susceptible cases, voriconazole resistance was associated with an increase in overall mortality of 21% on day 42 (49% vs 28%; P = .017) and 25% on day 90 (62% vs 37%; P = .0038). In non-intensive care unit patients, a 19% lower survival rate was observed in voriconazole-resistant cases at day 42 (P = .045). The mortality in patients who received appropriate initial voriconazole therapy was 24% compared with 47% in those who received inappropriate therapy (P = .016), despite switching to appropriate antifungal therapy after a median of 10 days. CONCLUSIONS: Voriconazole resistance was associated with an excess overall mortality of 21% at day 42 and 25% at day 90 in patients with IA. A delay in the initiation of appropriate antifungal therapy was associated with increased overall mortality.
BACKGROUND:Triazole resistance is an increasing problem in invasive aspergillosis (IA). Small case series show mortality rates of 50%-100% in patients infected with a triazole-resistant Aspergillus fumigatus, but a direct comparison with triazole-susceptible IA is lacking. METHODS: A 5-year retrospective cohort study (2011-2015) was conducted to compare mortality in patients with voriconazole-susceptible and voriconazole-resistant IA. Aspergillus fumigatus culture-positive patients were investigated to identify patients with proven, probable, and putative IA. Clinical characteristics, day 42 and day 90 mortality, triazole-resistance profiles, and antifungal treatments were investigated. RESULTS: Of 196 patients with IA, 37 (19%) harbored a voriconazole-resistant infection. Hematological malignancy was the underlying disease in 103 (53%) patients, and 154 (79%) patients were started on voriconazole. Compared with voriconazole-susceptible cases, voriconazole resistance was associated with an increase in overall mortality of 21% on day 42 (49% vs 28%; P = .017) and 25% on day 90 (62% vs 37%; P = .0038). In non-intensive care unit patients, a 19% lower survival rate was observed in voriconazole-resistant cases at day 42 (P = .045). The mortality in patients who received appropriate initial voriconazole therapy was 24% compared with 47% in those who received inappropriate therapy (P = .016), despite switching to appropriate antifungal therapy after a median of 10 days. CONCLUSIONS:Voriconazole resistance was associated with an excess overall mortality of 21% at day 42 and 25% at day 90 in patients with IA. A delay in the initiation of appropriate antifungal therapy was associated with increased overall mortality.
Authors: Thomas R Sewell; Yuyi Zhang; Amelie P Brackin; Jennifer M G Shelton; Johanna Rhodes; Matthew C Fisher Journal: Antimicrob Agents Chemother Date: 2019-08-23 Impact factor: 5.191
Authors: Matthew P Cheng; Alexander Lawandi; Todd C Lee; Philippe J Dufresne; Danila Seidel; Paul E Verweij; Oliver A Cornely; Donald C Sheppard Journal: J Clin Microbiol Date: 2019-05-24 Impact factor: 5.948
Authors: A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl Journal: Stud Mycol Date: 2021-05-10 Impact factor: 16.097
Authors: S Dellière; L Verdurme; J Bigot; E Dannaoui; Y Senghor; F Botterel; A Fekkar; M E Bougnoux; C Hennequin; J Guitard Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191
Authors: J Kevin Hicks; Rod E Quilitz; Rami S Komrokji; Timothy E Kubal; Jeffrey E Lancet; Yanina Pasikhova; Dahui Qin; Wonhee So; Gisela Caceres; Kerry Kelly; Yasmina S Salchert; Kevin Shahbazian; Farnoosh Abbas-Aghababazadeh; Brooke L Fridley; Ana P Velez; Howard L McLeod; John N Greene Journal: Clin Pharmacol Ther Date: 2019-11-01 Impact factor: 6.875